Abbott Laboratories
ABT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $195,872,361 | $190,869,785 | $192,461,870 | $249,813,500 |
| - Cash | $7,616,000 | $6,896,000 | $9,882,000 | $9,799,000 |
| + Debt | $15,275,000 | $15,873,000 | $17,946,000 | $19,251,000 |
| Enterprise Value | $203,531,361 | $199,846,785 | $200,525,870 | $259,265,500 |
| Revenue | $41,950,000 | $40,109,000 | $43,653,000 | $43,075,000 |
| % Growth | 4.6% | -8.1% | 1.3% | – |
| Gross Profit | $21,325,000 | $20,037,000 | $22,323,000 | $23,214,000 |
| % Margin | 50.8% | 50% | 51.1% | 53.9% |
| EBITDA | $10,834,000 | $10,605,000 | $11,888,000 | $12,159,000 |
| % Margin | 25.8% | 26.4% | 27.2% | 28.2% |
| Net Income | $13,402,000 | $5,723,000 | $6,933,000 | $7,071,000 |
| % Margin | 31.9% | 14.3% | 15.9% | 16.4% |
| EPS Diluted | 7.64 | 3.27 | 3.91 | 3.94 |
| % Growth | 133.6% | -16.4% | -0.8% | – |
| Operating Cash Flow | $8,558,000 | $7,261,000 | $9,581,000 | $10,533,000 |
| Capital Expenditures | -$2,207,000 | -$2,202,000 | -$1,777,000 | -$1,885,000 |
| Free Cash Flow | $6,351,000 | $5,059,000 | $7,804,000 | $8,648,000 |